The European Parliament has voted in favor of three major health policy initiatives: patients rights in cross-border health care; improving patient safety; and a European Union strategy on rare diseases (Marketletters passim). The latter aims to improve the recognition of rare, or "orphan," diseases which affect up to 6% of the total EU population, or 29 million to 36 million people, and pool expertise, experience and research to maximize the effective use of resources to the benefit of all patients with these conditions. It also calls for wider international collaboration in this area.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze